Effect of alpha-lipoic acid and Silybum marianum supplementation with a Mediterranean diet on metabolic dysfunction-associated steatosis
作者机构：Instituto de Investigaciones Médico-BiológicasUniversidad VeracruzanaVeracruz 91700Mexico
出 版 物：《World Journal of Hepatology》 (世界肝病学杂志(英文))
年 卷 期：2025年第17卷第1期
页 面：86-95页
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：Steatotic liver disease Silybum marianum Alpha-lipoic acid Mediterranean diet Fatty liver
摘 要：BACKGROUND The treatment of metabolic dysfunction-associated steatotic liver disease(MA-SLD)has focused on the control of *** marianum(SM)and alpha-lipoic acid(ALA)have shown antioxidant and adjuvant effects on the control of metabolic *** To evaluate whether the SM-ALA formulation(LUDLEV®),in combination with the Mediterranean diet(MD),could improve MASLD-related liver *** A randomized,double-blind clinical trial was conducted on patients with *** of SM-ALA plus MD(group A)vs placebo plus MD(group B)was compared for 24 *** baseline and weeks 12 and 24,anthropometric measurements,metabolic parameters,and liver function were *** effectiveness was evaluated through transient *** Fifty patients aged 54±10 years were included,and the majority(74%)were *** visceral fat and umbilical circumference were reported in both groups,with significance in group A(P=0.045 and 0.003,respectively).The de-crease in controlled attenuation parameter was gradual and maintained at 12 and 24 weeks in group A(P=0.026),whereas in group B the decrease was greater at week 12 and remained unchanged at week 24(∆controlled attenuation parameter:-27 dB/m).Mild adverse effects were reported in 4 patients in group A(16%)and 4 patients in group B(16%),with no significant differences between groups(P=0.641).CONCLUSION SM-ALA(LUDLEV®)combined with the MD can promote the improvement of metabolic parameters,reducing visceral fat and hepatic steatosis in Mexican patients with MASLD.
维普期刊数据库
